Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALStandard

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

Standard Dose
0.137MG/SPRAY;0.05MG/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE is listed in Drugs@FDA under application 208436 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE Form and strength SPRAY, METERED;NASAL - 0.137MG/SPRAY;0.05MG/SPRAY Sponsor TEVA PHARMS USA INC Submission history Latest submission status date: 2025-04-08 00:00:00.

Structured Monograph

Clinical summary

Approval overview AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE is listed in Drugs@FDA under application 208436 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE Form and strength SPRAY, METERED;NASAL - 0.137MG/SPRAY;0.05MG/SPRAY Sponsor TEVA PHARMS USA INC Submission history Latest submission status date: 2025-04-08 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE) | Drug Monograph | MedicHelpline